These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 18612199)

  • 61. The cholesterol paradox is flawed; cholesterol must be lowered in dialysis patients.
    Wan RK; Mark PB; Jardine AG
    Semin Dial; 2007; 20(6):504-9. PubMed ID: 17991195
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dyslipidemia of kidney disease.
    Attman PO; Samuelsson O
    Curr Opin Lipidol; 2009 Aug; 20(4):293-9. PubMed ID: 19512921
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dyslipidemia after renal transplantation: a cause for concern?
    Butani L
    Pediatr Transplant; 2008 Nov; 12(7):724-8. PubMed ID: 18444948
    [No Abstract]   [Full Text] [Related]  

  • 64. Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation.
    Ota T; Umeda H; Yokota S; Miyata S; Takamura A; Sugino S; Hayashi K; Ishiki R; Takeichi Y; Iwase M; Inagaki H; Murohara T
    Am Heart J; 2009 Jul; 158(1):92-8. PubMed ID: 19540397
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Potential role of growth factors with particular focus on growth hormone and insulin-like growth factor-1 in the management of chronic kidney disease.
    Feldt-Rasmussen B; El Nahas M
    Semin Nephrol; 2009 Jan; 29(1):50-8. PubMed ID: 19121474
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical correlation between dyslipidemia and pediatric chronic allograft nephropathy.
    Valavi E; Otukesh H; Fereshtehnejad SM; Sharifian M
    Pediatr Transplant; 2008 Nov; 12(7):748-54. PubMed ID: 18503482
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review.
    Johnson DW; Craven AM; Isbel NM
    Hemodial Int; 2007 Jan; 11(1):1-14. PubMed ID: 17257349
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chronic kidney disease: the new epidemic and its impact on West Virginia.
    Schmidt RJ; Latos DL
    W V Med J; 2009; 105(5):12-6, 18. PubMed ID: 19806865
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Kidney disease and cardiovascular disease: implications of dyslipidemia.
    Keane WF; Lyle PA
    Cardiol Clin; 2005 Aug; 23(3):363-72. PubMed ID: 16084284
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
    Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
    Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion.
    Brantsma AH; Bakker SJ; Hillege HL; de Zeeuw D; de Jong PE; Gansevoort RT;
    Nephrol Dial Transplant; 2008 Dec; 23(12):3851-8. PubMed ID: 18641082
    [TBL] [Abstract][Full Text] [Related]  

  • 72. IL-18 is involved in vascular injury in end-stage renal disease patients.
    Porazko T; Kúzniar J; Kusztal M; Kúzniar TJ; Weyde W; Kuriata-Kordek M; Klinger M
    Nephrol Dial Transplant; 2009 Feb; 24(2):589-96. PubMed ID: 18775894
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The risk of gallbladder stone formation is increased in patients with predialysis chronic kidney disease but not those undergoing chronic hemodialysis therapy.
    Kazama JJ; Kazama S; Koda R; Yamamoto S; Narita I; Gejyo F
    Nephron Clin Pract; 2009; 111(3):c167-72. PubMed ID: 19194106
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Strategies for improving long-term survival in patients with ESRD.
    Nolan CR
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S120-7. PubMed ID: 16251247
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Dyslipidemia in Dialysis Patients.
    Qunibi WY
    Semin Dial; 2015; 28(4):345-53. PubMed ID: 25855389
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Overweight, obesity and chronic kidney disease.
    Ting SM; Nair H; Ching I; Taheri S; Dasgupta I
    Nephron Clin Pract; 2009; 112(3):c121-7; discussion c127. PubMed ID: 19390212
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment.
    Kestenbaum B
    Semin Dial; 2007; 20(4):286-94. PubMed ID: 17635817
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dyslipidemia and anemia in chronically hemodialyzed patients.
    Malik J; Svobodová J; Tuka V; Mokrejsová M; Tesar V
    Prague Med Rep; 2007; 108(2):177-84. PubMed ID: 18225644
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis.
    Kovesdy CP; Anderson JE
    Semin Dial; 2007; 20(6):566-9. PubMed ID: 17991206
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dyslipidemia associated with chronic kidney disease.
    Tsimihodimos V; Mitrogianni Z; Elisaf M
    Open Cardiovasc Med J; 2011; 5():41-8. PubMed ID: 21643500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.